Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials

Restricted access

To address whether the use of bisphosphonates in the adjuvant setting of breast cancer might have any effect on the natural course of the disease, a meta-analysis was conducted of published and unpublished randomized controlled trials found in PubMed, the Cochrane Central Register of Controlled Trials, the ISI Web of Knowledge, and abstracts of major international conferences up to January 2009. All trials that randomized patients with primary breast cancer to undergo adjuvant treatment with any bisphosphonate versus non-use were considered eligible. Analysis included data from 13 eligible trials involving 6886 patients randomized to treatment with bisphosphonates (n = 3414) or either placebo or no treatment (n = 3472). Compared with no use, adjuvant breast cancer treatment with bisphosphonates did not reduce the overall number of deaths (odds ratio [OR], 0.708; 95% CI, 0.482–1.041; P = .079), bone metastases (OR, 0.925; 95% CI, 0.768–1.114; P = .413), overall disease recurrences (OR, 0.843; 95% CI, 0.602–1.181; P = .321), distant relapse (OR, 0.896; 95% CI, 0.674–1.192; P = .453), visceral recurrences (OR, 1.051; 95% CI, 0.686–1.609; P = .820), or local relapses (OR, 1.056; 95% CI, 0.750–1.487; P = .756). No significant heterogeneity was observed among the trials except for estimates of deaths and disease recurrences (P = .034 and P = .016, respectively). In subgroup analyses, use of zoledronic acid was associated with a statistically significant lower risk for disease recurrence (OR, 0.675; 95% CI, 0.479–0.952; P = .025). However, these results should be interpreted with caution because the statistical significance for this association was weak and might be attributed to chance from multi-test analyses. Use of zoledronic acid was not associated with any significant difference in death (OR, 0.642; 95% CI, 0.388–1.063) and bone metastasis rates (OR, 0.661; 95% CI, 0.379–1.151). Currently available evidence does not support the hypothesis that use of bisphosphonates in adjuvant treatment of early breast cancer will alter the natural course of the disease. Nonetheless, a nonsignificant trend seems to exist for better outcomes in patients undergoing bisphosphonate treatment. Until further evidence from new clinical trials becomes available, adjuvant bisphosphonates should not be recommended routinely.

Correspondence: Davide Mauri, MD, Daravelia 23, Roditsa-Lamias, TK 35100 Lamia, Greece. E-mail: dvd.mauri@gmail.com
  • 1.

    GreenJR. Bisphosphonates: preclinical review. Oncologist2004;9(Suppl 4):313.

  • 2.

    DaubineFLe GallCGasserJ. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst2007;99:322330.

    • Search Google Scholar
    • Export Citation
  • 3.

    van der PluijmGVloedgravenHvan BeekE. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest1996;98:698705.

    • Search Google Scholar
    • Export Citation
  • 4.

    BoissierSFerrerasMPeyruchaudO. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res2000;60:29492954.

    • Search Google Scholar
    • Export Citation
  • 5.

    SenaratneSGPirianovGMansiJL. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer2000;82:14591468.

  • 6.

    FromigueOKheddoumiNBodyJJ. Bisphosphonates antagonise bone growth factors’ effects on human breast cancer cells survival. Br J Cancer2003;89:178184.

    • Search Google Scholar
    • Export Citation
  • 7.

    FournierPBoissierSFilleurS. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res2002;62:65386544.

    • Search Google Scholar
    • Export Citation
  • 8.

    OttewellPDMonkonenHJonesM. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst2008;100:11671178.

    • Search Google Scholar
    • Export Citation
  • 9.

    BrufskyA. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist2008;13:187195.

  • 10.

    KristensenBEjlertsenBMouridsenHT. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol2008;47:740746.

    • Search Google Scholar
    • Export Citation
  • 11.

    GnantMMlineritschBSchippingerW. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med2009;360:679691.

  • 12.

    DielIJJaschkeASolomayerEF. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol2008;19:20072011.

    • Search Google Scholar
    • Export Citation
  • 13.

    ColemanRThorpeHCameronD. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy—first safety data from the AZURE trial (BIG01/04) [poster]. Presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14–17 2006; San Antonio Texas. Abstract 2080.

    • Search Google Scholar
    • Export Citation
  • 14.

    GreenspanSLBrufskyALemberskyBC. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol2008;26:26442652.

    • Search Google Scholar
    • Export Citation
  • 15.

    LesterJEDodwellDPurohitOP. Prevention of anastrazole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res2008;14:63366342.

    • Search Google Scholar
    • Export Citation
  • 16.

    MinceyBADentchevTSloanJA. N03CC—a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen [abstract]. J Clin Oncol2008;26(Suppl):Abstract 564.

    • Search Google Scholar
    • Export Citation
  • 17.

    Van PoznakCHannonRClackG. Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). Presented at the San Antonio Breast Cancer Symposium; December 10–14 2008; San Antonio Texas. Abstract 1137.

    • Search Google Scholar
    • Export Citation
  • 18.

    ShapiroCLHalabiSGibsonG. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who developed ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results of GALGB trial 79809 [abstract]. J Clin Oncol2008;26(Suppl):Abstract 512.

    • Search Google Scholar
    • Export Citation
  • 19.

    HinesSLMinceyBASloanJA. N02C1: a phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC) [abstract]. J Clin Oncol2008;26(Suppl):Abstract 525.

    • Search Google Scholar
    • Export Citation
  • 20.

    BryceCJPriorJCSillK. Does short-term, intravenous, low dose clodronate, administered with adjuvant chemotherapy for premenopausal breast cancer reduce bone loss in the first year in patients [abstract]?Proc Am Soc Clin Oncol2002;21:Abstract 270.

    • Search Google Scholar
    • Export Citation
  • 21.

    BrufskyABossermanLCaradonnaR. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 13–16 2007; San Antonio Texas. Abstract 27.

    • Search Google Scholar
    • Export Citation
  • 22.

    EidtmannHBundredNJDeBoerR. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 10–14 2008; San Antonio Texas. Abstract 44.

    • Search Google Scholar
    • Export Citation
  • 23.

    FuleihanGel-HSalamounMMouradYA. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab2005;90:32093214.

    • Search Google Scholar
    • Export Citation
  • 24.

    DelmasPDBalenaRConfravreuxE. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol1997;15:955962.

    • Search Google Scholar
    • Export Citation
  • 25.

    HershmanDLMcMahonDJCrewKD. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol2008;26:47394745.

    • Search Google Scholar
    • Export Citation
  • 26.

    TevaarwerkAStewartJALoveR. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women with breast cancer [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 19558.

    • Search Google Scholar
    • Export Citation
  • 27.

    SchenkNLombartAFrassoladtiA. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let). Eur J Cancer2007;5(Suppl 5):186187. Abstract 2008.

    • Search Google Scholar
    • Export Citation
  • 28.

    SaartoTVehmanenLVirkkunenPBlomqvistC. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol2004;43:650656.

    • Search Google Scholar
    • Export Citation
  • 29.

    VehmanenLSaartoTRisteliJ. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat2004;87:181188.

    • Search Google Scholar
    • Export Citation
  • 30.

    PowlesTPatersonSMcCloskeyE. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res2006;82:R13

    • Search Google Scholar
    • Export Citation
  • 31.

    HaTCLiH. Meta-analysis of clodronate and breast cancer survival. Br J Cancer2007;96:17961801.

  • 32.

    StewartLAParmarMKB. Meta-analysis of the literature or of individual patient data: is there a difference?Lancet1993;341:418422.

  • 33.

    DuchateauLPignonJPBijnensL. Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. Controlled Clinical Trials2001;22:538547.

    • Search Google Scholar
    • Export Citation
  • 34.

    BrufskyAHarkerWGBeckJT. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol2007;25:829836.

    • Search Google Scholar
    • Export Citation
  • 35.

    De BoerREidtmannHLluchA. The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. Breast Cancer Res Treat2007;106(Suppl 1):S36. Abstract 501.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 175 177 17
PDF Downloads 7 7 0
EPUB Downloads 0 0 0